HEALTH CARE
How Reducing Negligible Risks Drives Up Health Costs
The over-prescription of statins is costing Americans billions, and the media is complicit with the problem. An independent national institute that compared the effectiveness of treatments could reduce unnecessary spending.

One out of every four dollars Americans spend goes toward products the safety of which rests in the hands of the Food and Drugs Administration. But as Virginia Cox points out in her chapter on the agency in the forthcoming book Change for America: A Progressive Blueprint for the 44th President, “Consumers today are understandably skeptical about the safety of their food and medical products, yet the [FDA] is struggling to keep pace with breakthroughs in science, an expanding global market, and years of underfunding.”
Three big pharmaceutical companies, Pfizer, Merck, and Eli Lilly, announced last week that they will join forces and create a joint venture called Enlight BioSciences that will help speed drug development. A look at profits and drug approvals.
Healthcare professionals helping patients with mental health problems have an increasing array of treatment and prevention tools at their disposal. But on the horizon is a preventative tool that poses challenging public policy questions about ethics and privacy: personal genomic sequencing.
The University of Virginia is being accused of encouraging doctors to prescribe Johnson & Johnson’s anti-seizure and migraine drug Topamax “off-label” to treat alcoholism. But is the medicine safe for treating alcoholics without FDA approval?